2-(2-pyridylmethyl)benzonitrile | 7547-81-1

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 2-(2-pyridylmethyl)benzonitrile
• 英文别名: 2-pyridin-2-ylmethyl-benzonitrile；2-(2-Cyan-benzyl)-pyridin；2-(Pyridin-2-ylmethyl)benzonitrile
• CAS: 7547-81-1
• 化学式: C₁₃H₁₀N₂
• 分子量: 194.236
• InChiKey: NUWNVUSOPSYUID-UHFFFAOYSA-N

物化性质

• 沸点：
  330.1±22.0 °C(Predicted)
• 密度：
  1.14±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  15
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.08
• 拓扑面积：
  36.7
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  2-氯吡啶 、 2-氰基溴苄 在 锌 作用下， 以 四氢呋喃 为溶剂， 以75%的产率得到2-(2-pyridylmethyl)benzonitrile
  参考文献：
  名称：

  与Negishi反应偶联的有机锌卤化物的连续合成

  摘要：

  AbstractThe Negishi cross‐coupling is a powerful CC bond forming reaction. The method is less commonly used relative to other cross‐coupling methods in part due to lack of availability of organozinc species. While organozinc species can be prepared, problems with reproducibility and handling of these sensitive species can complicate these reactions. Herein, we describe the continuous formation, using an activated packed‐bed of metallic zinc, and subsequent use of organozinc halides. We demonstrate that a single column of zinc can provide excellent yields of organozinc halides and that they can be used downstream in subsequent Negishi cross‐couplings. The preparation of the zinc column and the scope of the reaction are discussed.magnified image

  DOI：

  10.1002/adsc.201400243

文献信息

• [EN] NOVEL MICROBICIDES<br/>[FR] NOUVEAUX MICROBICIDES
  申请人：SYNGENTA PARTICIPATIONS AG

  公开号：WO2012056003A1

  公开（公告）日：2012-05-03

  Compounds of formula (I), wherein G represents together with the two carbon atoms of the pyrimidine ring to which it is attached, a 5- to 7-membered aliphatic carbocyclic or heterocyclic ring system which contain 0 to 2 heteroatoms selected from the group consisting of nitrogen, oxygen and sulfur; and wherein said 5- to 7-membered aliphatic carbocyclic or heterocyclic ring system can be mono-, di- or trisubstituted by substituents selected from the group consisting of halogen, keto, C1-C6alkyl, C1-C6alkoxy, C1-C6alkyloximino and C1-C6alkylendioxy; and wherein the other substituents R1, R2, R3, R4, R5 and R6 are as defined in claim 1, and their use as microbicides.

  式（I）的化合物，其中G代表与其连接的嘧啶环的两个碳原子一起，含有0至2个来自氮、氧和硫组成的杂原子的5至7元杂原子的脂环或杂环系统；其中所述的5至7元脂环或杂环系统可以通过来自卤素、酮基、C1-C6烷基、C1-C6烷氧基、C1-C6烷氧基亚胺和C1-C6烷基二氧基的取代基进行单取代、双取代或三取代；以及其他取代基R1、R2、R3、R4、R5和R6如权利要求1所定义，并且它们作为微生物杀菌剂的用途。
• NOVEL MICROBICIDES
  申请人：Trah Stephan

  公开号：US20130281467A1

  公开（公告）日：2013-10-24

  Compounds of formula (I), wherein G represents together with the two carbon atoms of the pyrimidine ring to which it is attached, a 5- to 7-membered aliphatic carbocyclic or heterocyclic ring system which contain 0 to 2 heteroatoms selected from the group consisting of nitrogen, oxygen and sulfur; and wherein said 5- to 7-membered aliphatic carbocyclic or heterocyclic ring system can be mono-, di- or trisubstituted by substituents selected from the group consisting of halogen, keto, C 1 -C 6 alkyl, C 1 -C 6 alkoxy, C 1 -C 6 alkyloximino and C 1 -C 6 alkylendioxy; and wherein the other substituents R 1 , R 2 , R 3 , R 4 , R 5 and R 6 are as defined in claim 1 , and their use as microbicides.

  式(I)的化合物，其中G与其所连接的嘧啶环的两个碳原子一起表示5-至7-成员的脂肪环烷基或杂环烷基环系统，该环系统中包含0至2个选自氮、氧和硫的杂原子; 且所述的5-至7-成员的脂肪环烷基或杂环烷基环系统可以被取代基选自卤素、酮、C1-C6烷基、C1-C6烷氧基、C1-C6烷氧肟基和C1-C6烷基二氧基取代，且其他取代基R1、R2、R3、R4、R5和R6如权利要求1所定义，并且它们的用途是作为微生物杀灭剂。
• Anti-infective pyrimidines and uses thereof
  申请人：ABBOTT LABORATORIES

  公开号：EP2639226A1

  公开（公告）日：2013-09-18

  The present invention relates to a crystalline form of N-(6-(3-tert-butyl-5-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-2-methoxyphenyl)naphthalen-2-yl)methanesulfonamide or a crystalline form of a salt of N-(6-(3-tert-butyl-5-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-2-methoxyphenyl)naphthalen-2-yl)methanesulfonamide as well as pharmaceutical compositions comprising said crystalline forms, therapeutic uses of said crystalline forms and processes for making said crystalline forms.

  本发明涉及 N-(6-(3-叔丁基-5-(2,4-二氧代-3,4-二氢嘧啶-1(2H)-基)-2-甲氧基苯基)萘-2-基)甲磺酰胺的结晶形式或 N-(6-(3-叔丁基-5-(2,4-二氧代-3,4-二氢嘧啶-1(2H)-基)-2-甲氧基苯基)萘-2-基)甲磺酰胺盐的结晶形式以及包含所述结晶的药物组合物、或 N-(6-(3-叔丁基-5-(2,4-二氧代-3,4-二氢嘧啶-1(2H)-基)-2-甲氧基苯基)萘-2-基)甲磺酰胺的结晶形式，以及包含所述结晶形式的药物组合物、所述结晶形式的治疗用途和制造所述结晶形式的工艺。
• URACIL OR THYMINE DERIVATIVE FOR TREATING HEPATITIS C
  申请人：AbbVie Bahamas Ltd.

  公开号：EP2222646B1

  公开（公告）日：2014-01-22
• ANTI-INFECTIVE PYRIMIDINES AND USES THEREOF
  申请人：AbbVie Bahamas Ltd.

  公开号：EP2368882B1

  公开（公告）日：2014-08-13